CellaVision AB (publ) (CLVSF)
- Previous Close
20.36 - Open
20.36 - Bid --
- Ask --
- Day's Range
20.36 - 20.36 - 52 Week Range
16.72 - 21.32 - Volume
1 - Avg. Volume
17 - Market Cap (intraday)
508.371M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
40.72 - EPS (TTM)
0.50 - Earnings Date --
- Forward Dividend & Yield 0.21 (1.05%)
- Ex-Dividend Date May 6, 2024
- 1y Target Est
--
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Proficiency Software, a web-based software designed to help laboratory managers assess, monitor, and promote staff competency in cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. Further, the company offers reagents to identify cell and tissue morphology, parasites, and bacteria in diagnosing various diseases; and instruments, including RAL SmearBox, RAL Stainbox, and RAL Stainer. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
www.cellavision.comRelated News
Performance Overview: CLVSF
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLVSF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLVSF
Valuation Measures
Market Cap
523.43M
Enterprise Value
518.20M
Trailing P/E
40.76
Forward P/E
29.33
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.84
Price/Book (mrq)
7.41
Enterprise Value/Revenue
0.77
Enterprise Value/EBITDA
2.50
Financial Highlights
Profitability and Income Statement
Profit Margin
19.24%
Return on Assets (ttm)
11.47%
Return on Equity (ttm)
19.19%
Revenue (ttm)
677.29M
Net Income Avi to Common (ttm)
130.31M
Diluted EPS (ttm)
0.50
Balance Sheet and Cash Flow
Total Cash (mrq)
121.64M
Total Debt/Equity (mrq)
9.03%
Levered Free Cash Flow (ttm)
72.96M
Company Insights: CLVSF
CLVSF does not have Company Insights